ToxPearl | *Clinical Insight*

No. 10 · Emerging Adulterants · July 2026 ToxiPharm LLC

Medetomidine Withdrawal Begins Within 4 to 6 Hours After Last Use. Standard Opioid Withdrawal Protocols Are Not Sufficient.

Clinical Scenario

A patient with fentanyl use disorder presents to an OTP intake 5 hours after last use with agitation, tremors, and refractory nausea; buprenorphine induction does not resolve the sympathetic symptoms, and vital signs show hypertension and tachycardia disproportionate to COWS score.

The Pearl

Medetomidine is a potent α2-adrenergic agonist and racemic mixture that includes dexmedetomidine. Regular use produces physiologic α2-receptor dependence; abrupt cessation triggers rebound sympathetic activation with withdrawal typically beginning 4 to 6 hours after last use, substantially earlier than opioid withdrawal, producing agitation, tremors, hypertension, tachycardia, and diaphoresis.[1] The COWS instrument does not capture this physiology, and buprenorphine alone will not resolve it.

Treatment requires oral or transdermal α2-agonist replacement (clonidine), often at **above-label doses.**[1] Severe nausea and vomiting are frequently refractory to standard antiemetics; when enteral therapy is not tolerated or ineffective, IV dexmedetomidine is required at infusion rates that may exceed typical ICU sedation protocols.[1] Concurrent opioid or other substance withdrawal must be treated separately.[1,2]

Why It Matters

Medetomidine seizure reports rose from 247 in 2023 to over 8,000 in 2025; the DEA named it alongside xylazine, nitazenes, and cychlorphine in its May 2026 public safety advisory.[3] The withdrawal syndrome carries greater autonomic instability than xylazine withdrawal with a faster onset. OTPs, emergency departments, and detox programs using standard opioid withdrawal assessments will systematically undertreat these patients unless α2-agonist therapy is initiated promptly.

Bottom Line: Suspect medetomidine withdrawal when a patient with fentanyl use disorder develops agitation, tremors, and refractory nausea within 4 to 6 hours of last use, particularly when sympathetic signs exceed COWS score predictions. Initiate α2-agonist therapy (clonidine, oral or transdermal) at above-label doses; escalate to IV dexmedetomidine if enteral therapy fails. Treat concurrent substance withdrawal separately.

References

1. Zimmerman DE, Goodstein D, Durney PA, Patel-Francis SH, London KS. Presentation and management of acute medetomidine withdrawal. *Am J Health Syst Pharm.* 2026. doi:10.1093/ajhp/zxag141 [Therapy Update]

2. Lynch MJ, Pizon AF, Yealy DM. Emergence of medetomidine in the illicit drug supply: implications for emergency care and withdrawal management. *Ann Emerg Med.* 2026;87(6):709-716. doi:10.1016/j.annemergmed.2025.12.004 [Review]

3. Drug Enforcement Administration. Public safety advisory: fentanyl laced with xylazine, nitazenes, medetomidine, and cychlorphine. May 12, 2026. Available at: dea.gov/press-releases/2026/05/12/public-safety-advisory [Regulatory]

William L. Bundy Jr., PharmD | ToxiPharm LLC | toxipharm@toxipharm.org

